DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and ...

Use of AI assistance reduced the misclassification of HER2-low and HER2-ultralow breast cancers as HER2-null by 24%, said study presenter Marina De Brot, MD, PhD, of AC Camargo Cancer Center in ...

Daiichi and AZ have estimated that approximately 60% to 65% of HR-positive, HER2-negative breast cancers are HER2-low and potentially an additional 25% may be HER2-ultra-low.

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...

For the HER2-overexpressing gastric cancer patients, DV + PD-1 + trastuzumab has the potential to become the new standard first-line treatment; for the HER2-low-expressing gastric cancer patients ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

One word: slay.

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.